You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Fibroblast growth factor receptors (FGFR) Inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

Active, not recruiting
  • Neoplasm
  • Beijing, China
  • +5 more
Jan 31, 2023

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Urinary Bladder Tumors, Receptors, Fibroblast Growth Factor Trial in Japan (Erdafitinib Intravesical Delivery System)

Not yet recruiting
  • Urinary Bladder Neoplasms
  • Receptors, Fibroblast Growth Factor
  • Erdafitinib Intravesical Delivery System
  • Kanagawa, Japan
  • +3 more
Jan 27, 2023

Squamous-cell NSCLC Trial in Switzerland (Rogaratinib)

Active, not recruiting
  • Squamous-cell Non-small Cell Lung Cancer
  • Baden, Switzerland
  • +10 more
Jan 20, 2022

Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor Trial in

Recruiting
  • Locally Advanced Gastrointestinal Stromal Tumor
  • +7 more
  • Biopsy
  • +4 more
  • Duarte, California
  • +17 more
Feb 2, 2023

Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification Trial in Worldwide (Futibatinib, Futibatinib plus

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Phoenix, Arizona
  • +36 more
Jan 27, 2023

Advanced or Recurrent Solid Tumors, FGFR Gene Alterations Trial in Japan (E7090)

Recruiting
  • Advanced or Recurrent Solid Tumors
  • FGFR Gene Alterations
  • Aoba-ku, Sendai, Miyagi, Japan
  • +4 more
May 9, 2022

Cancer Trial in St. Gallen (Rogaratinib (BAY1163877), Combination drug)

Completed
  • Cancer
  • Rogaratinib (BAY1163877)
  • Combination drug
  • St. Gallen, Sankt Gallen, Switzerland
    Kantonsspital St. Gallen
Mar 20, 2022

Bladder Cancer Trial in Indianapolis, Baltimore, Rockledge (Dovitinib)

Terminated
Has Results
  • Bladder Cancer
  • Indianapolis, Indiana
  • +2 more
Jul 7, 2022

Lung Cancer, NSCLC, Pulmonary Tumor Trial in Germany (ERDAFITINIB)

Unknown status
  • Lung Cancer
  • +4 more
  • Gauting, Bavaria, Germany
  • +10 more
Nov 11, 2020

Advanced or Metastatic Solid Tumor Trial in Worldwide (Rogaratinib (BAY1163877), Copanlisib (BAY80-6946))

Completed
  • Advanced or Metastatic Solid Tumor
  • Rogaratinib (BAY1163877)
  • Copanlisib (BAY80-6946)
  • Los Angeles, California
  • +19 more
Jul 13, 2022

Tumors Trial in Worldwide (Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib

Completed
Has Results
  • Neoplasms
  • Rogaratinib (BAY1163877) oral solution
  • +2 more
  • Chicago, Illinois
  • +28 more
Apr 12, 2021

Cholangiocarcinoma Trial in China, Japan (E7090)

Active, not recruiting
  • Cholangiocarcinoma
  • Bengbu, Anhui, China
  • +55 more
Jan 24, 2023

Intrahepatic Cholangiocarcinoma Trial (Famitinib)

Withdrawn
  • Intrahepatic Cholangiocarcinoma
  • (no location specified)
Jun 16, 2021

Advanced Solid Tumor Trial in Worldwide (Erdafitinib)

Recruiting
  • Advanced Solid Tumor
  • Tucson, Arizona
  • +199 more
Jan 27, 2023

Solid Tumors Trial (Bemarituzumab)

Recruiting
  • Solid Tumors
  • Duarte, California
  • +54 more
Feb 1, 2023

Squamous-Cell Non-Small-Cell Lung Cancer Trial in Worldwide (Bemarituzumab, Docetaxel)

Recruiting
  • Squamous-Cell Non-Small-Cell Lung Cancer
  • Orange, California
  • +24 more
Jul 27, 2022

Cholangiocarcinoma Trial in Worldwide (Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice)

Not yet recruiting
  • Cholangiocarcinoma
  • Tinengotinib 8 mg
  • +2 more
  • Santa Monica, California
  • +13 more
Jul 7, 2023

Urothelial Carcinoma Trial in Worldwide (Derazantinib dose level 1 (300mg once daily) monotherapy, Derazantinib various dose

Completed
  • Urothelial Carcinoma
  • Derazantinib dose level 1 (300mg once daily) monotherapy
  • +4 more
  • Newnan, Georgia
  • +65 more
Oct 19, 2022

MPN (Myeloproliferative Tumors) Trial in Worldwide (Pemigatinib)

Active, not recruiting
  • MPN (Myeloproliferative Neoplasms)
  • Phoenix, Arizona
  • +32 more
Jun 24, 2022

Hepatocellular Carcinoma, TACE, Anlotinib Trial in Lanzhou, Xi'an (Anlotinib Hydrochloride, TACE)

Active, not recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Anlotinib Hydrochloride
  • TACE
  • Lanzhou, Gansu, China
  • +3 more
Jan 12, 2023

Bladder Transitional Cell Carcinoma, Bladder Cancer, Fibroblast Growth Factor Receptor Trial (Infigratinib)

Withdrawn
  • Bladder Transitional Cell Carcinoma
  • +2 more
  • (no location specified)
Aug 8, 2022

Chronic Kidney Diseases Trial (Placebo, Vitamin K 2)

Not yet recruiting
  • Chronic Kidney Diseases
  • Placebo
  • Vitamin K 2
  • (no location specified)
Jul 4, 2023

Chronic Kidney Diseases Trial (Placebo, Co-Enzyme Q10)

Not yet recruiting
  • Chronic Kidney Diseases
  • Placebo
  • Co-Enzyme Q10
  • (no location specified)
Jul 4, 2023

Hepatocellular Carcinoma Trial in Hangzhou (Anlotinib Hydrochloride)

Terminated
  • Hepatocellular Carcinoma
  • Anlotinib Hydrochloride
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital of Medical School of Zhejiang Univ
Aug 25, 2022